August 7, 2025

An inducible BRCA1 expression system with in vivo applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistance

View Full Paper

Ask AI

Bookmark

Main finding indicates that Δexon11 brca1 expression leads to significant resistance against olaparib and carboplatin.
Drug sensitivity relates to the levels of Δexon11 expression, demonstrating a hypomorphic response to therapy.
The approach involved engineering a doxycycline-inducible brca1 system in a triple-negative breast cancer model to assess therapy responses.
Significance lies in proposing atr inhibitors combined with parp inhibitors as a strategic method to combat resistance in brca1-mutant cancers.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Engineered model shows that combination of atr and parp inhibitors improves resistance in brca1-mutant tumors, indicating a potential therapeutic strategy.

Cite This Study

Irving et al. (2025) studied this question.

synapsesocial.com/papers/689dfe90d61984b91e13bc63 https://doi.org/10.1101/2025.08.05.668495

View Full Paper

Ask AI

Bookmark

Implication

Engineered model shows that combination of atr and parp inhibitors improves resistance in brca1-mutant tumors, indicating a potential therapeutic strategy.

An inducible BRCA1 expression system with in vivo applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistance

Key Points

Discussion

Implication

Cite This Study

An inducible BRCA1 expression system with in vivo applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistance

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider